Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
Pharma Technical Development Analytics, F. Hoffmann-La Roche AG, 4070 Basel, Switzerland.
Anal Chem. 2023 Jun 6;95(22):8478-8486. doi: 10.1021/acs.analchem.3c00222. Epub 2023 May 23.
After decades of research, gene therapy products have reached market maturity in recent years. Recombinant adeno-associated viruses (rAAVs) are one of the most promising gene delivery vehicles and are currently under intense scientific investigation. These next-generation medicines remain very challenging when it comes to designing appropriate analytical techniques for quality control. One critical quality attribute is the integrity of ssDNA incorporated in these vectors. The genome is the active compound driving rAAV therapy and therefore requires proper assessment and quality control. Current techniques for rAAV genome characterization include next-generation sequencing, quantitative polymerase chain reaction, analytical ultracentrifugation (AUC), and capillary gel electrophoresis (CGE), yet each of them presents their limitations or lack of user-friendliness. In this work, we demonstrate for the first time the potential of ion pairing-reverse phase-liquid chromatography (IP-RP-LC) to characterize the integrity of rAAV genomes. The obtained results were supported by two orthogonal techniques, AUC and CGE. IP-RP-LC can be performed above DNA melting temperatures, avoiding the detection of secondary DNA isoforms, and does not require the use of dyes due to UV detection. We demonstrate that this technique is suitable for batch comparability, different rAAV serotypes (AAV2 and AAV8), internal vs external (inside vs outside the capsid) DNA analysis, and contaminated samples. Overall, it is exceptionally user-friendly, needs limited sample preparation, has high reproducibility, and permits fractionation for further peak characterization. All of these factors add significant value of IP-RP-LC to the analytical toolbox of rAAV genome assessment.
经过几十年的研究,近年来基因治疗产品已达到市场成熟阶段。重组腺相关病毒(rAAV)是最有前途的基因传递载体之一,目前正受到科学界的强烈关注。在设计适当的分析技术以进行质量控制方面,这些下一代药物仍然极具挑战性。一个关键的质量属性是这些载体中整合的 ssDNA 的完整性。基因组是驱动 rAAV 治疗的活性化合物,因此需要进行适当的评估和质量控制。目前用于 rAAV 基因组特征分析的技术包括下一代测序、定量聚合酶链反应、分析超速离心(AUC)和毛细管凝胶电泳(CGE),但每种技术都存在局限性或缺乏易用性。在这项工作中,我们首次证明了离子对反相液相色谱(IP-RP-LC)在表征 rAAV 基因组完整性方面的潜力。获得的结果得到了 AUC 和 CGE 两种正交技术的支持。IP-RP-LC 可以在 DNA 融解温度以上进行,避免了对二级 DNA 异构体的检测,并且由于使用紫外检测,因此不需要使用染料。我们证明该技术适用于批次可比性、不同的 rAAV 血清型(AAV2 和 AAV8)、内部与外部(衣壳内与衣壳外)DNA 分析以及污染样品。总体而言,它非常易于使用,需要的样品制备量有限,重现性高,并允许进行馏分分离以进一步进行峰特征分析。所有这些因素都使 IP-RP-LC 在 rAAV 基因组评估的分析工具包中具有显著的附加价值。